Medicine for treating amyotrophic lateral sclerosis and method for enhancing blood-brain barrier opening effect

Abstract

The invention relates to the technical field of ultrasound combined microbubbles, in particular to medicine for treating amyotrophic lateral sclerosis by using an ultrasound combined microbubble technology and a method for enhancing a blood-brain barrier opening effect. Through the medicine and the method provided by the invention, the brain medicine/blood medicine proportion percentage of edaravone entering the brain can be increased. In mouse experiments, the medicine is combined with ultrasound for opening the blood-brain barrier of a mouse to deliver edaravone into the brain; after 4 weeksof treatment, the paw gripping force of the mouse in an ultrasound combined microbubble administration group is improved by 10.57 percent (p is smaller than 0.05) through being compared with that ofa model group; and the retention time on a rotating rod is prolonged by 79.8 percent (p is smaller than 0.01) through being compared with that of the mouse in the model group, and is prolonged by 57.3percent (p is smaller than 0.05) through being compared with that of an Eda group. The results show that compared with a conventional administration mode, the mode of delivering edaravone into the brain by ultrasound combined microbubbles has the advantages that the Brain bioavailability can be improved; and the disease progression of SOD1 mice is more effectively delayed.

Description

technical field [0001] The invention relates to the technical field of ultrasound combined with microbubbles, in particular to a drug for treating amyotrophic lateral sclerosis using ultrasound combined with microbubbles technology, and a method for improving the opening effect of the blood-brain barrier. Background technique [0002] Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, ALS, motor neuron disease, is a progressive and fatal neurological degenerative disease. ALS is caused by the degeneration of motor neurons in the central nervous system that control skeletal muscles. Due to the degeneration and death of upper and lower motor neurons, the patient's muscles gradually weaken and shrink; eventually, the brain completely loses the ability to control voluntary movements; eventually, it will cause difficulties in pronunciation, swallowing, and breathing. ALS usually lasts 3 to 5 years from onset to respiratory paralysis and death. Amyotrophic...

AI Technical Summary

Problems solved by technology

[0004] The present invention aims at the problem that the efficiency of entering the brain of the existing edaravone administration method and the effect of treating ALS need to be further improved, and improves a medicine for treating amyotrophic lateral sclerosis using ultrasound combined with microbubble technology, and Methods for Improving the Opening Effect of the Blood Brain Barrier

Images